American Healthcare REIT, Inc. (AHR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial metrics, optimistic guidance, and strategic growth initiatives. Increased NFFO and NOI guidance, high occupancy rates, and substantial acquisitions indicate robust performance. Medicare Advantage growth and long-term care demand provide additional revenue streams. The Q&A section supports this sentiment, highlighting strategic acquisitions, competitive advantages, and margin expansion. The company's disciplined approach and strong operator relationships further bolster confidence. Despite some uncertainties, the overall outlook is highly favorable, suggesting a strong positive stock price reaction.
Key Financial Performance
Total portfolio same-store NOI growth 11.8% in Q4 2025 and 14.2% for the full year 2025, driven by occupancy gains, disciplined rate management, and continued expense controls.
Trilogy same-store NOI Increased 14% in Q4 2025 and 18.4% for the full year 2025. Same-store occupancy reached 90.6% in Q4, up 275 basis points year-over-year, supported by rate and quality mix improvements.
SHOP same-store NOI Increased 24.6% in Q4 2025 and 25.2% for the full year 2025. Same-store occupancy surpassed 90% in Q4, averaging 90.6%, up approximately 290 basis points year-over-year, driven by RevPOR growth and operational focus.
Normalized funds from operations (NFFO) $0.46 per diluted share in Q4 2025 and $1.72 per diluted share for 2025, representing 22% year-over-year growth, driven by double-digit NOI growth and accretive acquisitions.
Debt to EBITDA Improved by nearly a full turn in 2025, reflecting better financial leverage and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Trilogy and SHOP segments: These segments now contribute 76.9% of consolidated cash NOI for the business, with strong performance driven by occupancy gains, disciplined rate management, and expense controls. Same-store NOI growth for Trilogy was 18.4% for 2025, and SHOP delivered 25.2% growth.
SHOP acquisitions: Over $950 million of new investments were made in 2025, primarily in the SHOP segment, with $117.5 million in acquisitions closed in early 2026. These acquisitions were focused on newer assets in attractive submarkets, leveraging relationships with regional operators.
Same-store NOI growth: Total portfolio same-store NOI growth was 14.2% for 2025, marking the second consecutive year of double-digit growth. Growth was driven by occupancy gains, pricing discipline, and expense controls.
Revenue management: Dynamic revenue management is being piloted with operators and properties, expected to sustain above-average NOI growth into the next decade.
Capital allocation strategy: The company remains focused on relationship-driven sourcing, disciplined underwriting, and long-term cash flow durability. Investments are aligned with long-term strategy, emphasizing high-quality care and outcomes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The interim CEO role was taken over by Jeff Hanson due to the medical leave of the previous CEO, Danny. While the transition is described as seamless, leadership changes can pose risks to strategic continuity and operational stability.
Market Supply and Demand: Although new supply growth in the long-term care sector is low, there is a risk that any incremental supply could impact market dynamics. Additionally, reliance on demographic trends like the aging baby boomer population may not materialize as expected.
Revenue Management and Pricing Strategies: The company relies on dynamic revenue management and pricing strategies to sustain NOI growth. However, any misalignment in pricing or occupancy strategies could adversely affect financial performance.
Acquisition and Investment Risks: The company has been highly active in acquisitions, with over $950 million in investments in 2025. While these are aimed at long-term growth, there is a risk of overextension or misjudgment in market dynamics, especially in newer or less familiar markets.
Debt and Leverage: Although the company has improved its debt-to-EBITDA ratio, it still carries financial leverage. Any adverse market conditions or operational setbacks could strain its ability to manage debt effectively.
Regulatory and Payer Mix: The company’s reliance on Medicare and Medicare Advantage penetration for revenue growth introduces risks related to regulatory changes or shifts in payer policies.
Operational Dependence on Partners: The company’s performance is heavily reliant on its operating partners. Any underperformance or misalignment with these partners could impact operational and financial outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 NFFO Guidance: The company issued 2026 NFFO guidance of $1.99 to $2.05 per diluted share, implying another year of double-digit NFFO per share growth.
Total Portfolio Same-Store NOI Growth Guidance for 2026: Guidance is set between 7% and 11%, with segment-level same-store NOI growth ranges as follows: 8% to 12% growth in Trilogy, 15% to 19% growth in SHOP, 0% to 2% growth in Outpatient Medical, and 2% to 3% growth in Triple-Net Leased Properties.
SHOP Segment Growth Expectations: SHOP is expected to continue leading the portfolio's organic growth in 2026, supported by dynamic revenue management and strong supply-demand imbalances in the long-term care sector.
Trilogy Segment Growth Expectations: Trilogy is expected to deliver another year of double-digit same-store NOI growth in 2026, driven by historically strong occupancy levels and embedded pricing tailwinds.
Capital Allocation and Development Plans: The company plans to focus on Trilogy expansions and campus growth initiatives, leveraging existing campuses to mitigate risks and generate faster cash flow. Over $230 million of awarded deals are in the pipeline for 2026.
Market Trends and Supply Dynamics: New starts and supply growth are at historically low levels, with deliveries of new stock below 1% of existing inventory. This is expected to maintain competitive positioning for the next several years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you dive deeper into the acquisition environment, specifically regarding subsegments like higher acuity or lower acuity and any changes to terms of management agreements?
A:The company is focusing on higher acuity SHOP assets, particularly assisted living (AL) and memory care, which provide long-term stability. Independent living (IL) assets make up about 20% of acquisitions, often as part of a continuum of care. Pricing varies, with lower cap rates for IL assets, but the focus remains on higher acuity assets for competitive advantage.
Q:Can you decompartmentalize the SHOP guidance for this year in terms of RevPOR and occupancy, and how it compares to 2025?
A:The SHOP portfolio saw over 250 basis points of occupancy increase in 2025. Same-store NOI growth was 50% in 2024, 25% in 2025, and is projected at 17% for 2026. Occupancy is at 90.6%, providing pricing power. The company expects occupancies to reach 95%-100% over the next 5-10 years, but exact 2026 levels are uncertain.
Q:What is the update on Trilogy's occupancy upside and the impact of quality mix on sustaining pricing?
A:Trilogy's integrated campus model (skilled nursing, assisted living, independent living, memory care) drives NOI growth. The focus is on shifting to higher payer sources like Medicare and Medicare Advantage, reducing Medicaid reliance. Villa projects and private pay mix are being expanded. Trilogy optimizes for NOI growth without sacrificing rate or occupancy.
Q:What are the moving parts driving Trilogy's same-store NOI growth outlook, and what could lead to upside?
A:Occupancy gains could outpace expectations, especially in post-acute business as length of stay pressures normalize. Medicare Advantage rates and private pay revenue management could also drive growth. Trilogy's proprietary revenue management platform dynamically prices units, providing a competitive advantage.
Q:Can the private pay portion offset lower rate growth from government reimbursement in Trilogy?
A:While private pay and mix shift opportunities could offset lower government reimbursement rates, it depends on various factors breaking in Trilogy's favor. Predicting this is speculative, but contracts are in place to support the right direction.
Q:What is the status of rolling out Trilogy's revenue management system to other SHOP operators?
A:The rollout is in early stages, with pilot programs targeting both highly occupied operators and those with lower market rates. The system dynamically prices units and uses real-time market data. Results are not yet available, but the system aims to help resource-constrained operators improve performance.
Q:What is the timing for the $230 million acquisition pipeline, and what is causing delays?
A:There are no delays; the pipeline is dynamic. The company closed $500 million in acquisitions recently and added $275 million to the pipeline. Deal activity is high, with a mix of marketed and off-market deals. The company remains competitive and focused on high-quality acquisitions.
Q:How will the upcoming CMS rate impact Trilogy's revenue and payer mix?
A:Medicare and Medicare Advantage rates will be influenced by the CMS rate. Trilogy optimizes within Medicare for higher acuity residents, achieving a 5.2% rate increase versus the national average of 3%. Medicare Advantage contracts, negotiated as a discount to Medicare, benefit from Trilogy's high quality ratings.
Q:What are the expected yields for the investment pipeline, and is there a focus on higher demographic seniors?
A:Year 1 yields are in the high 5% to low 6% range, stabilizing in the 7% range. The focus remains on newer, higher-quality properties and higher acuity communities. The company targets affluent markets to support higher rents and long-term performance.
Q:What is the NOI flow-through for incremental revenue in SHOP and Trilogy segments?
A:In SHOP, incremental occupancy at high levels can yield 70%-80% NOI flow-through. Trilogy's assisted living, memory care, and independent living segments have similar flow-through, while skilled nursing has lower pull-through due to care requirements. Margins expand as occupancy increases.
Q:What differentiates incoming operators in turning around mismanaged SHOP assets?
A:Experienced operators with market presence, proper staffing, and effective marketing are key. They focus on resident and employee experiences, driving faster turnaround due to surging demand for senior housing.
Q:Is there increased competition for SHOP transactions, and how does the Trilogy relationship impact this?
A:Competition has increased, but the company benefits from off-market deals through operator relationships, comprising about half of acquisitions. Trilogy's development capabilities provide a competitive edge, with $150-$200 million in annual development opportunities.
Q:What is the bridge between normalized FFO growth and same-store NOI growth, especially in SHOP?
A:SHOP acquisitions in 2025 are not in the 2026 same-store pool, but their growth benefits shareholders. Non-same-store assets, often undermanaged properties, are expected to perform well. Same-store pool adjustments will reflect these acquisitions in 2027, supporting multiyear growth.
Q:How does the company approach partnering with less experienced operators?
A:The company prefers experienced operators with proven track records. However, it supports smaller regional operators with strong potential by providing resources to scale and grow, leveraging Trilogy's platform for additional support.
Q:What is the impact of Trilogy's platform on SHOP margin expansion?
A:SHOP margin expansion (300 basis points) is driven by strong operator performance and early-stage benefits from Trilogy's platform. The platform's full potential is yet to be realized, with more value expected in the future.
Q:What seasonality impacts are seen in SHOP occupancy for Q1?
A:Flu season had a significant impact last year, but 2026 has seen less flu-related occupancy decline so far. The company remains cautious but optimistic about maintaining occupancy levels.
Q:What caused the decline in hospital coverage in the triple-net portfolio, and are there concerns about rent payments?
A:The decline is due to the tenant's transition from a surgical to a community hospital, adding new services. The lease is guaranteed by a AA- rated hospital system, and the tenant has invested heavily in the property, mitigating rent payment concerns.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on acquisition volumes for 2026, stating they would remain disciplined and competitive but refrained from committing to specific targets. Additionally, they were speculative about the ability of private pay to offset lower government reimbursement rates, citing multiple variables that would need to align.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHR portfolio
AHR predecessor
Advantage insurer
Advantage penetration
CEO Interim
CEO President
CEO co
CEO continuity
CEO leave
Chairman CEO
Chairman Interim
Chairman formation
Finance statement
Instructions Peterson
Interim CEO
Interim President
NOI AHR
alignment
basis point
care health
cash NOI
cash flow
company
conference today
confidence
conviction
decade
depth
dynamic
health outcome
home
improvement quality
leverage
occupancy basis
outcome investment
percent
project
quality mix
role
segment portfolio
store occupancy
supply demand
term cash
term value
vision
volume
AHR Transcript
American Healthcare REIT, Inc. (AHR) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call summary reveals strong financial metrics, optimistic guidance, and strategic growth initiatives. Increased NFFO and NOI guidance, high occupancy rates, and substantial acquisitions indicate robust performance. Medicare Advantage growth and long-term care demand provide additional revenue streams. The Q&A section supports this sentiment, highlighting strategic acquisitions, competitive advantages, and margin expansion. The company's disciplined approach and strong operator relationships further bolster confidence. Despite some uncertainties, the overall outlook is highly favorable, suggesting a strong positive stock price reaction.
American Healthcare REIT, Inc. (AHR) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary highlights strong financial performance with raised guidance and improved leverage. The Q&A section supports this with expected NOI growth, strategic acquisitions, and stable asset pricing. Despite some vague responses, the overall sentiment is positive due to robust demand, improved margins, and strategic focus on Medicare Advantage, suggesting a likely stock price increase in the near term.
American Healthcare REIT, Inc. (AHR) Presents At BofA Securities 2025 Global Real Estate Conference Transcript
Neutral9-10
American Healthcare REIT, Inc. (AHR) Q2 2025 Earnings Call Transcript
Positive8-8
The company reported strong financial performance with significant year-over-year growth in key segments like Trilogy and SHOP, improved debt metrics, and increased NFFO per share. The Q&A highlighted further growth prospects, including strategic acquisitions, expanding Medicare Advantage contracts, and positive occupancy trends. The upward revision of guidance across segments and a comprehensive revenue management strategy also support a strong positive outlook. Despite some uncertainties in Medicare Advantage rate growth, overall, the earnings call suggests a robust financial and operational position, likely leading to a strong positive stock price reaction.
AHR Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
